Clinical Trials Logo

Recurrent Mycosis Fungoides clinical trials

View clinical trials related to Recurrent Mycosis Fungoides.

Filter by:

NCT ID: NCT02520791 Active, not recruiting - Clinical trials for Recurrent Grade 1 Follicular Lymphoma

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Start date: September 13, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.